{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T16:47:16Z","timestamp":1782751636331,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,29]]},"DOI":"10.7759\/cureus.111741","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T16:23:10Z","timestamp":1782750190000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Efficacy and Safety of Mycophenolate Mofetil Versus Cyclophosphamide As Induction Therapy for Lupus Nephritis: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Basel","family":"Mousa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nedal H","family":"Elrewany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Abdelnasser A","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Tubaileh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Silman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie Fayez","family":"Kobal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiqa","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheeza","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanin Abdelrahman","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05780616","article-title":"Update on lupus nephritis","volume":"12","author":"Almaani S","year":"2017","unstructured":"Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017, 12:825-35. 10.2215\/CJN.05780616","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-025-04434-3","article-title":"Taming renal inflammation: signaling pathways and therapeutic advances in lupus nephritis","volume":"26","author":"Braunstein M","year":"2025","unstructured":"Braunstein M. Taming renal inflammation: signaling pathways and therapeutic advances in lupus nephritis. BMC Nephrol. 2025, 26:507. 10.1186\/s12882-025-04434-3","journal-title":"BMC Nephrol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.23954\/osj.v6i1.2811","article-title":"Lupus nephritis: pathogenesis and treatment update review","volume":"6","author":"Habas E","year":"2021","unstructured":"Habas E, Khan FY. Lupus nephritis: pathogenesis and treatment update review. Open Sci J. 2021, 6:1. 10.23954\/osj.v6i1.2811","journal-title":"Open Sci J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/09612033261432164","article-title":"LUNELORD: a descriptive, prospective study on the demographics, disease characteristics and health-related quality of life of patients with lupus nephritis and long-term organ damage in rheumatology clinics in the Arabian Gulf","volume":"35","author":"Al-Saleh J","year":"2026","unstructured":"Al-Saleh J, Elbadawi F, Namas R, et al.. LUNELORD: a descriptive, prospective study on the demographics, disease characteristics and health-related quality of life of patients with lupus nephritis and long-term organ damage in rheumatology clinics in the Arabian Gulf. Lupus. 2026, 35:653-66. 10.1177\/09612033261432164","journal-title":"Lupus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.90051","article-title":"Lupus, a leading cause of years of potential life lost in young women: implications for public health priorities and research funding","volume":"8","author":"Yen EY","year":"2026","unstructured":"Yen EY, Park EJ, Singh RR. Lupus, a leading cause of years of potential life lost in young women: implications for public health priorities and research funding. ACR Open Rheumatol. 2026, 8:90051. 10.1002\/acr2.90051","journal-title":"ACR Open Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening JJ","year":"2004","unstructured":"Weening JJ, D'Agati VD, Schwartz MM, et al.. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004, 65:521-30. 10.1111\/j.1523-1755.2004.00443.x","journal-title":"Kidney Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.10.017","article-title":"Update on lupus nephritis: core curriculum","volume":"76","author":"Parikh SV","year":"2020","unstructured":"Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: core curriculum. Am J Kidney Dis. 2020, 76:265-81. 10.1053\/j.ajkd.2019.10.017","journal-title":"Am J Kidney Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11020343","article-title":"Induction and maintenance treatment of lupus nephritis: a comprehensive review of meta-analyses","volume":"11","author":"Shin JI","year":"2022","unstructured":"Shin JI, Li H, Park S, et al.. Induction and maintenance treatment of lupus nephritis: a comprehensive review of meta-analyses. J Clin Med. 2022, 11:343. 10.3390\/jcm11020343","journal-title":"J Clin Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.09.007","article-title":"EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update","volume":"85","author":"Fanouriakis A","year":"2026","unstructured":"Fanouriakis A, Kostopoulou M, Anders HJ, et al.. EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. Ann Rheum Dis. 2026, 85:75-90. 10.1016\/j.ard.2025.09.007","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1191\/0961203304lu2012oa","article-title":"Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide","volume":"13","author":"Katsifis GE","year":"2004","unstructured":"Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus. 2004, 13:673-8. 10.1191\/0961203304lu2012oa","journal-title":"Lupus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.70021","article-title":"The 2024 APLAR consensus on the management of lupus nephritis","volume":"28","author":"Mok CC","year":"2025","unstructured":"Mok CC, So H, Hamijoyo L, et al.. The 2024 APLAR consensus on the management of lupus nephritis. Int J Rheum Dis. 2025, 28:70021. 10.1111\/1756-185X.70021","journal-title":"Int J Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-023-00572-y","article-title":"Comparison of the effectiveness and safety of mycophenolate mofetil and cyclophosphamide in lupus nephritis: evidence from a real-world study","volume":"10","author":"Zhang X","year":"2023","unstructured":"Zhang X, Huang H, Gao D, et al.. Comparison of the effectiveness and safety of mycophenolate mofetil and cyclophosphamide in lupus nephritis: evidence from a real-world study. Rheumatol Ther. 2023, 10:1199-213. 10.1007\/s40744-023-00572-y","journal-title":"Rheumatol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022328","article-title":"Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: a systematic review and meta-analysis","volume":"99","author":"Jiang YP","year":"2020","unstructured":"Jiang YP, Zhao XX, Chen RR, Xu ZH, Wen CP, Yu J. Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: a systematic review and meta-analysis. Medicine (Baltimore). 2020, 99:22328. 10.1097\/MD.0000000000022328","journal-title":"Medicine (Baltimore)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181e93d00","article-title":"Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis","volume":"89","author":"Kamanamool N","year":"2010","unstructured":"Kamanamool N, McEvoy M, Attia J, Ingsathit A, Ngamjanyaporn P, Thakkinstian A. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine (Baltimore). 2010, 89:227-35. 10.1097\/MD.0b013e3181e93d00","journal-title":"Medicine (Baltimore)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.08.041","article-title":"Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials","volume":"61","author":"Henderson LK","year":"2013","unstructured":"Henderson LK, Masson P, Craig JC, Roberts MA, Flanc RS, Strippoli GF, Webster AC. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2013, 61:74-87. 10.1053\/j.ajkd.2012.08.041","journal-title":"Am J Kidney Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2165\/11635030-000000000-00000","article-title":"Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials","volume":"72","author":"Liu LL","year":"2012","unstructured":"Liu LL, Jiang Y, Wang LN, Yao L, Li ZL. Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials. Drugs. 2012, 72:1521-33. 10.2165\/11635030-000000000-00000","journal-title":"Drugs"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli L","year":"2017","unstructured":"Andreoli L, Bertsias GK, Agmon-Levin N, et al.. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome. Ann Rheum Dis. 2017, 76:476-85. 10.1136\/annrheumdis-2016-209770","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-025-07118-0","article-title":"Efficacy of mycophenolate mofetil versus cyclophosphamide in the management of childhood-onset lupus nephritis: a systematic review and meta-analysis","author":"Sarkar S","year":"2026","unstructured":"Sarkar S, Mukhopadhyay K, Das A, et al.. Efficacy of mycophenolate mofetil versus cyclophosphamide in the management of childhood-onset lupus nephritis: a systematic review and meta-analysis. Pediatr Nephrol. 2026, 10.1007\/s00467-025-07118-0","journal-title":"Pediatr Nephrol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003583","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"18","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021, 18:1003583. 10.1371\/journal.pmed.1003583","journal-title":"PLoS Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S66677","article-title":"Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank","volume":"6","author":"Margulis AV","year":"2014","unstructured":"Margulis AV, Pladevall M, Riera-Guardia N, et al.. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol. 2014, 6:359-68. 10.2147\/CLEP.S66677","journal-title":"Clin Epidemiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler EM","year":"2005","unstructured":"Ginzler EM, Dooley MA, Aranow C, et al.. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005, 353:2219-28. 10.1056\/NEJMoa043731","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2005.00444.x","article-title":"Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis","volume":"10","author":"Ong LM","year":"2005","unstructured":"Ong LM, Hooi LS, Lim TO, et al.. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton). 2005, 10:504-10. 10.1111\/j.1440-1797.2005.00444.x","journal-title":"Nephrology (Carlton)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel GB","year":"2009","unstructured":"Appel GB, Contreras G, Dooley MA, et al.. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009, 20:1103-12. 10.1681\/ASN.2008101028","journal-title":"J Am Soc Nephrol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.318","article-title":"Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis","volume":"89","author":"Rathi M","year":"2016","unstructured":"Rathi M, Goyal A, Jaryal A, et al.. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Kidney Int. 2016, 89:235-42. 10.1038\/ki.2015.318","journal-title":"Kidney Int"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-018-0973-7","article-title":"Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial","volume":"19","author":"Sedhain A","year":"2018","unstructured":"Sedhain A, Hada R, Agrawal RK, Bhattarai GR, Baral A. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial. BMC Nephrol. 2018, 19:175. 10.1186\/s12882-018-0973-7","journal-title":"BMC Nephrol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319836712","article-title":"Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis","volume":"28","author":"Smith E","year":"2019","unstructured":"Smith E, Al-Abadi E, Armon K, et al.. Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis. Lupus. 2019, 28:613-20. 10.1177\/0961203319836712","journal-title":"Lupus"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320926256","article-title":"Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil","volume":"29","author":"Prasad N","year":"2020","unstructured":"Prasad N, Kurian J, Agarwal V, et al.. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil. Lupus. 2020, 29:845-53. 10.1177\/0961203320926256","journal-title":"Lupus"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-022-01438-2","article-title":"Induction therapy for pediatric onset class IV lupus nephritis: mycophenolate mofetil versus cyclophosphamide","volume":"36","author":"Chbihi M","year":"2023","unstructured":"Chbihi M, Eveillard LA, Riller Q, et al.. Induction therapy for pediatric onset class IV lupus nephritis: mycophenolate mofetil versus cyclophosphamide. J Nephrol. 2023, 36:829-39. 10.1007\/s40620-022-01438-2","journal-title":"J Nephrol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1159\/000545014","article-title":"The efficacy of induction treatment with a cyclophosphamide- or mycophenolate mofetil-based regimen for active lupus nephritis in Thailand: a retrospective cohort study","volume":"5","author":"Poungsuwan P","year":"2025","unstructured":"Poungsuwan P, Supasyndh O, Satirapoj B. The efficacy of induction treatment with a cyclophosphamide- or mycophenolate mofetil-based regimen for active lupus nephritis in Thailand: a retrospective cohort study. Glomerular Dis. 2025, 5:151-7. 10.1159\/000545014","journal-title":"Glomerular Dis"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000866","article-title":"Mycophenolate mofetil versus cyclophosphamide for initial therapy in childhood-onset proliferative lupus nephritis: a prospective, multicenter, randomized trial","volume":"37","author":"Wang Y","year":"2026","unstructured":"Wang Y, Li X, Jian S, et al.. Mycophenolate mofetil versus cyclophosphamide for initial therapy in childhood-onset proliferative lupus nephritis: a prospective, multicenter, randomized trial. J Am Soc Nephrol. 2026, 37:560-8. 10.1681\/ASN.0000000866","journal-title":"J Am Soc Nephrol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-026-00630-2","article-title":"Effectiveness of IV cyclophosphamide and mycophenolate mofetil in the treatment of childhood-onset lupus nephritis in a resource-limited setting","volume":"10","author":"Guiang-Valerio AK","year":"2026","unstructured":"Guiang-Valerio AK, Collante MT, Bernal CB. Effectiveness of IV cyclophosphamide and mycophenolate mofetil in the treatment of childhood-onset lupus nephritis in a resource-limited setting. BMC Rheumatol. 2026, 10:26. 10.1186\/s41927-026-00630-2","journal-title":"BMC Rheumatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.12.008","article-title":"Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials","volume":"70","author":"Palmer SC","year":"2017","unstructured":"Palmer SC, Tunnicliffe DJ, Singh-Grewal D, et al.. Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials. Am J Kidney Dis. 2017, 70:324-36. 10.1053\/j.ajkd.2016.12.008","journal-title":"Am J Kidney Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/504464-comparative-efficacy-and-safety-of-mycophenolate-mofetil-versus-cyclophosphamide-as-induction-therapy-for-lupus-nephritis-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T16:23:11Z","timestamp":1782750191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/504464-comparative-efficacy-and-safety-of-mycophenolate-mofetil-versus-cyclophosphamide-as-induction-therapy-for-lupus-nephritis-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.111741","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}